Biology and management of relapsed acute myeloid leukaemia.
about
Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?Late relapses in acute myeloid leukemia: analysis of characteristics and outcomeA phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a siPhase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.The mortality and response rate after FLANG regimen in patients with refractory/relapsed acute leukemia.Salvage therapy for relapsed or refractory acute myeloid leukemiaKaryotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients.Evaluation of prognostic factors in patients with relapsed AML: Clonal evolution versus residual disease.Genetic and epigenetic heterogeneity and the impact on cancer relapse.Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center.A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).The development and validation of a decision-analytic model representing the full disease course of acute myeloid leukemia.External quality assessment for prothrombin time/international normalised ratio using point-of-care devices: split-sample or conventional external quality assessment using control samples?
P2860
Q26828997-3B8BC8CE-60CB-4AD3-85DA-35599728BCF4Q33861781-437CE8FC-F43B-429F-8CBC-9CAEFF71AE47Q33939624-CC71E3AF-A7F8-4AB3-808F-A7B2C2915215Q35278018-11997190-3F02-4413-8BC1-4259F7504907Q36151239-A259D0A9-B307-454D-8DAB-B5D90AF1308EQ36467485-7F69AD85-0CE8-4538-81CA-A282AC75291CQ36529403-8CAD5317-4CB3-49FF-B7A1-7A160698491AQ36612564-6C35157E-0609-4A70-BE4A-BECE39C859B5Q36761796-C39A852A-3410-4217-923D-463C24D978D5Q37318667-E3761584-63D7-4D03-8D4A-01F8254D3060Q39433546-DB2C1EAA-5216-48AD-B9A9-FEEA4C31DBB9Q40438036-007300E5-41C1-4176-80F7-9BD5A6177DB1Q40614153-4C9E27F0-1C3B-41C7-BC32-82412307B91DQ43085409-A3AA362E-E8C4-4044-8F65-397EE28CAB39Q43140221-4C107040-D8D8-44EC-94F6-EA25962520DAQ44115673-726C8BB0-CE86-4ED4-A364-AEC0B66FA30DQ45095746-412E269B-7D6E-4E5A-83E3-94A108AF1D77Q53226683-0FD9FA18-73F3-49D4-A19B-995EF1531944
P2860
Biology and management of relapsed acute myeloid leukaemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Biology and management of relapsed acute myeloid leukaemia.
@ast
Biology and management of relapsed acute myeloid leukaemia.
@en
type
label
Biology and management of relapsed acute myeloid leukaemia.
@ast
Biology and management of relapsed acute myeloid leukaemia.
@en
prefLabel
Biology and management of relapsed acute myeloid leukaemia.
@ast
Biology and management of relapsed acute myeloid leukaemia.
@en
P2093
P2860
P1476
Biology and management of relapsed acute myeloid leukaemia
@en
P2093
David Grimwade
Sudhir Tauro
P2860
P356
10.1111/J.1365-2141.2004.05318.X
P407
P577
2005-04-01T00:00:00Z